Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis receives EU approval for heart disease treatment

Sanofi-aventis receives EU approval for heart disease treatment

24th March 2010

Sanofi-aventis has been granted European regulatory approval for its new combination tablet treatment for coronary conditions.

The company and its partner Bristol-Myers Squibb have received European Commission backing for DuoPlavin/DuoCover, a dual antiplatelet treatment which combines clopidogrel and acetylsalicylic acid.

This treatment is specified for adult patients suffering from conditions such as unstable angina or non-Q-wave myocardial infarction and is designed to help to prevent against atherothrombotic events.

According to the two pharmaceutical companies, the product has been approved on the basis of “robust evidence” collated from large-scale clinical studies.

The firms added: “The new formulation of DuoPlavin/DuoCover carrying both antiplatelets in one single tablet contributes to reducing daily pill burden for patients.”

Earlier this month, Sanofi-aventis published new data from a phase III clinical trial of its prostate cancer treatment cabazitaxel, illustrating the drug’s efficacy benefits when compared to an alternative mitoxantrone therapy.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.